Stoke Therapeutics, Inc.
STOK
$31.16
-$1.34-4.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -169.77M | -6.89M | 40.57M | 52.49M | 50.27M |
| Total Depreciation and Amortization | 1.73M | 1.77M | 1.89M | 1.99M | 2.09M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.49M | 34.35M | 31.19M | 30.05M | 29.02M |
| Change in Net Operating Assets | -15.28M | 16.35M | -20.81M | -22.93M | -11.84M |
| Cash from Operations | -146.82M | 45.59M | 52.85M | 61.60M | 69.54M |
| Capital Expenditure | -871.00K | -670.00K | -480.00K | -451.00K | -343.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -148.88M | -186.14M | -124.45M | -163.58M | -103.49M |
| Cash from Investing | -149.75M | -186.81M | -124.93M | -164.03M | -103.83M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 180.34M | 97.39M | 5.62M | 10.66M | 130.75M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 180.34M | 97.39M | 5.62M | 10.66M | 130.75M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.23M | -43.84M | -66.47M | -91.78M | 96.46M |